Clinical drug investigation
-
Randomized Controlled Trial
Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.
Dabigatran etexilate is a pro-drug of the oral reversible direct thrombin inhibitor dabigatran that interacts with the active site in the catalytic domain of the thrombin molecule. ⋯ This thorough QT study demonstrated that therapeutic and fourfold supratherapeutic doses of dabigatran etexilate do not prolong QT intervals.